Want to see ENOV full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.85Last Year’s EPS
0.79Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.Company Guidance
Top-line Growth and Days-Adjusted Performance
Reported Q1 sales of $589 million, up 5% year-over-year. Company organic revenue +3% and days-adjusted organic growth +6% (selling days headwind ~240 bps). Reported results included a +420 bps FX tailwind and a -210 bps headwind related to the Dr. Comfort divestiture.
Recon Segment Outperformance
Recon delivered strong performance: company days-adjusted Recon growth +8% and organic Recon +6%. U.S. Recon grew 8% organically, led by extremities at +10% and hips & knees at +6%. International Recon grew 3% organic with double-digit growth in Extremities. Nebula rollout is unlocking hip opportunities; ARG and other new systems are driving shoulder and extremities share gains.
Prevention & Recovery (P&R) Momentum in Specific Categories
P&R reported +1% organic growth (3% on a days-adjusted basis). Global bracing grew ~3% (days-adjusted) and bone stimulation delivered high single-digit growth, reflecting pockets of strength within the segment as portfolio reshaping continues.
Improved Margins and EPS Growth
Adjusted gross margin of 62%, with an underlying improvement of ~40 basis points driven by favorable mix, productivity, and synergies. Adjusted EBITDA margin was 17.6% (underlying down ~10 bps due to higher R&D and expense phasing). Adjusted EPS was $0.89, representing ~10% underlying growth versus prior year. Effective tax rate ~21%; interest expense ~$9 million (flat).
Cash Flow Progress and Capital Discipline
Free cash flow improved by $16 million year-over-year in Q1. Management reiterates expectation of free cash flow conversion >25% for 2026. CapEx is being invested to support Recon growth (instrumentation comprises ~half of CapEx) and is expected to be roughly in line with prior year as a percentage of sales.
Innovation Launches and ASC Traction
Robust innovation pipeline with recent launches: Arvis (AAOS showcase and early shoulder cases, including first OUS shoulder in South Africa) and Nebula instrument sets driving conversions. ASC penetration is growing (primary knees >25% in ASCs, shoulders in the teens), and Arvis's flexible commercial model (purchase/lease/fee-per-case) positions the company to accelerate ASC adoption and competitive conversions.
ENOV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ENOV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $24.85 | $27.25 | +9.66% |
Feb 26, 2026 | $22.32 | $25.42 | +13.89% |
Nov 06, 2025 | $31.49 | $28.42 | -9.75% |
Aug 07, 2025 | $25.76 | $28.52 | +10.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Enovis Corporation (ENOV) report earnings?
Enovis Corporation (ENOV) is schdueled to report earning on Jul 30, 2026, TBA (Confirmed).
What is Enovis Corporation (ENOV) earnings time?
Enovis Corporation (ENOV) earnings time is at Jul 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ENOV EPS forecast?
ENOV EPS forecast for the fiscal quarter 2026 (Q2) is 0.85.